Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P567

The long-term efficacy of concomitant enteral nutritional therapy during maintenance infliximab in patients with Crohn's disease: a prospective observational trial

Authors:

T. Yamamoto*, M. Nakahigashi, T. Shimoyama, K. Matsumoto

Yokkaichi Hazu Medical Centre, Inflammatory Bowel Disease Centre, Yokkaichi, Japan

P568.

Adherence to quality measures for inflammatory bowel disease in Korea: Questionnaire study based on American Gastroenterological Association Adult Inflammatory Bowel Disease Physician Performance Measures Set

Authors:

H.K. Song1, S.-A. Jung1, J.M. Cha2, S.N. Hong3, G.S. Seo4, K.-M. Lee5, Y.-H. Kim3, D.S. Han6, S.-K. Yang7, 1Ewha Womans University School of Medicine, Internal Medicine, Seoul, Korea, Republic of, 2Kyung Hee University College of Medicine, Internal Medicine, Seoul, Korea, Republic of, 3Sungkyunkwan University School of Medicine, Internal Medicine, Seoul, Korea, Republic of, 4Wonkwang University College of Medicine, Internal Medicine, Iksan, Korea, Republic of, 5College of Medicine, The Catholic University of Korea, Internal Medicine, Seoul, Korea, Republic of, 6Hanyang University College of Medicine, Internal Medicine, Guri, Korea, Republic of, 7Ulsan University College of Medicine, Internal Medicine, Seoul, Korea, Republic of

P568. Sustained efficacy in patients with ulcerative colitis treated with adalimumab: results from ULTRA 2
Authors:

S. Ghosh1, D. Wolf2, W. Sandborn3, J.-F. Colombel4, A. Lazar5, S. Eichner6, A. Robinson7, R. Thakkar7, 1University of Calgary, Calgary, Canada, 2Atlanta Gastroenterology Associates, Atlanta, United States, 3University of California, San Diego, La Jolla, United States, 4Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Lille, France, 5AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, 6Abbott Laboratories, United States, 7Abbott Laboratories, Abbott Park, United States

P568

Alterations of Intestinal Microbiota in Ulcerative Colitis Patients Treated with Sequential Antibiotic Combination and Faecal Microbiota Transplantation

Authors:

D. Ishikawa*1, T. Osada1, T. Sasaki2, K. Kuwahara-Arai2, K. Haga1, T. Shibuya1, T. Kodani1, K. Hiramatsu2, S. Watanabe1

1Juntendo University, Department of Gastroenterology, Tokyo, Japan, 2Juntendo University, Department Bacteriology, Tokyo, Japan

P569.

Adalimumab was more effective in the patients with bio-naive and early Crohn's disease

Authors:

T. Hisamatsu1, K. Matsuoka1, M. Naganuma2, J. Miyoshi1,3, N. Inoue4, T. Yajima1, S. Mizuno1, K. Saigusa1, Y. Nakazato1, K. Mori1, K. Takeshita1, K. Nanki1, H. Kiyohara1, Y. Iwao4, H. Ogata2, T. Kanai1, 1Keio University, School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokyo, Japan, 2Keio University, Center for Diagnostic and Therapeutic Endoscopy, Tokyo, Japan, 3Tokyo Dental University, Ichikawa General Hospital, Department of Internal Medicine, Ichikawa, Japan, 4Keio University, Center for Preventive Medicine, Tokyo, Japan

P569. Clinical correlations of infliximab trough levels (IFX-TL) and antibodies to infliximab (ATI) in inflammatory bowel disease
Authors:

M. Daperno1, A. Lavagna1, M. Fracchia1, C. Guiotto2, L. Germano2, C. Rigazio1, E. Ercole1, M. Migliardi2, R. Pellerito3, R. Rocca1, 1AO Ordine Mauriziano, Gastroenterology Unit, Torino, Italy, 2AO Ordine Mauriziano, Laboratory Unit, Torino, Italy, 3AO Ordine Mauriziano, Rheumatology Unit, Torino, Italy

P569

Systemic and peritoneal inflammatory response after laparoscopic vs open emergency colectomy for acute severe ulcerative colitis

Authors:

T. Yamamoto*, T. Shimoyama, K. Matsumoto

Yokkaichi Hazu Medical Centre, Inflammatory Bowel Disease Centre, Yokkaichi, Japan

P570.

Adalimumab maintenance therapy in infliximab exposed pediatric Crohn's disease; a Dutch nationwide survey

Authors:

M. Cozijnsen1, V. Duif2, F. Kokke3, A. Kindermann4, P. van Rheenen5, T. de Meij6, M. Schaart7, G. Damen2, O. Norbruis8, R. Pelleboer9, A. Van den Neucker10, H. van Wering11, T. Hummel12, J. Escher13, L. de Ridder13, 1Erasmus Medical Center, Pediatric Gastroenterology, Rotterdam, Netherlands, 2Radboud University Nijmegen Medical Center, Pediatric Gastoenterology, Nijmegen, Netherlands, 3Wilhelmina Children's Hospital-Utrecht Medical Center, Pediatric Gastoenterology, Utrecht, Netherlands, 4Emma Children's Hospital-Academic Medical Center, Pediatric Gastoenterology, Amsterdam, Netherlands, 5Beatrix Children's Hospital-University Medical Center Groningen, Pediatric Gastoenterology, Groningen, Netherlands, 6VU University Medical Center, Pediatric Gastoenterology, Amsterdam, Netherlands, 7Willem-Alexander Kinderziekenhuis-Leiden University Medical Center, Pediatric Gastoenterology, Leiden, Netherlands, 8Princess Amalia department of pediatrics, Isala, Pediatric Gastoenterology, Zwolle, Netherlands, 9Catharina Hospital, Pediatric Gastoenterology, Eindhoven, Netherlands, 10Maastricht University Medical Center, Pediatric Gastoenterology, Maastricht, Netherlands, 11Amphia Hospital, Pediatric Gastoenterology, Breda, Netherlands, 12Medisch Spectrum Twente, Pediatric Gastoenterology, Enschede, Netherlands, 13Erasmus MC-Sophia Children's Hospital, Pediatric Gastroenterology, Rotterdam, Netherlands

P570. Clinical and basic studies to understand factors associated with the loss of response to infliximab in patients with Crohn's disease
Authors:

A. Yamada1, K. Sono1, K. Takeuchi1, Y. Suzuki1, 1Sakura Medical Center, Toho university, Internal Medicine, Sakura city, Japan

P570

The Young Adult's Perception of Life with Inflammatory Bowel Disease and a Stoma: A qualitative examination

Authors:

L. Horgan*1, H. Richards2, A. Joy3

1Beaumont Hospital, Gastroenterology, Dublin, Ireland, 2Mercy University Hospital, University College Cork, Department of Psychology , Cork, Ireland, 3University College Cork, School of Medicine, Cork, Ireland

P571.

Adalimumab maintains remission for up to 4 years in patients with ulcerative colitis

Authors:

J.-F. Colombel1, W.J. Sandborn2, S. Ghosh3, D. Wolf4, R. Panaccione3, B. Feagan5, W. Reinisch6, A.M. Robinson7, A. Lazar8, M. Kron8, B. Huang7, R.B. Thakkar7, 1Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, 2University of California, San Diego, Division of Gastroenterology, La Jolla, United States, 3University of Calgary, Department of Medicine, Calgary, Canada, 4Atlanta Gastroenterology Associates, Atlanta, United States, 5Robarts Research Institute, London, Canada, 6McMaster University, Department of Medicine, Hamilton, Canada, 7AbbVie Inc, GPRD, North Chicago, United States, 8AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany

P571. Changing patients with ulcerative colitis to once daily mesalazine improves outcome and reduces cost in primary and secondary care
Authors:

H. Prasher1, P. Savania1, R. Jazrawi2, 1Medicines Management Solutions, Leicester, United Kingdom, 2Dr Falk Pharma UK, Bucks, United Kingdom

P571

Long-term operation rate and related prognostic factors in patients with Crohn's Disease treated by infliximab maintenance treatment

Authors:

H. Tanaka*, M. Miyakawa, R. Sakemi, M. Nasuno, S. Motoya, A. Imamura

Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan

P572.

Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND

Authors:

W.J. Sandborn1, D. Wolf2, J.-F. Colombel3, J. Panes4, S. Eichner5, A. Iezzi5, Q. Zhou5, A.M. Robinson5, M. Castillo5, R. Thakkar5, 1University of California, San Diego, Division of Gastroenterology, La Jolla, United States, 2Atlanta Gastroenterology Associates, Atlanta, United States, 3Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, 4Hospital Clinic University of Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 5AbbVie Inc, GPRD, North Chicago, United States

P572. Changes of the smoking habit after diagnosis of Crohn's disease
Authors:

R. de Francisco1, S. Riestra1, I. Perez1, L. Blanco1, O. Castano1, M. Varela1, L. Rodrigo1, 1Huca, Gastroenterology, Oviedo, Spain

P572

Paradoxical articular manifestations in inflammatory bowel diseases patients treated by anti-TNF

Authors:

H. Thiebault*1, P. Boyard-Lasselin2, C. Guignant3, N. Guillaume4, A. Wacrenier1, F. Brazier1, E. Nguyen-Khac1, V. Goëb2, J.-L. Dupas1, M. Fumery1

1Amiens University Hospital, Hepatogastroenterology, Amiens, France, 2Amiens University Hospital, Rheumatology, Amiens, France, 3Amiens University Hospital, Immunology, Amiens, France, 4Amiens University Hospital, Haematology, Amiens, France

P573.

A combination of low-dose thiopurine and allopurinol (ThioComp) is long-term efficacious and well-tolerated in IBD patients

Authors:

S. Almer1, A. Wagner2, M. Måhl1, U. Hindorf3, 1Karolinska Institutet, Department of Medicine, Stockholm, Sweden, 2Blekinge Central Hospital, Department of Medicine, Karlskrona, Sweden, 3University Hospital, Gastoenterology and Hepatology, Lund, Sweden

P573. Changes in resource utilisation in patients with Crohn's disease treated with adalimumab in routine clinical practice
Authors:

C. Saro1, D. Ceballos2, F. Muñoz3, C. De la Coba1, M.D. Aguilar4, P. Lazaro4, 1Cabueñes Hospital, Spain, 2Dr. Negrín Hospital, Spain, 3Hospital de León, León, Spain, 4TAISS, Madrid, Spain

P573

eHealth optimises documentation and enables live access to IBD Multi Disciplinary Team outcomes

Authors:

C.A. Parisinos*1, P. Harrow2, L. Langmead2, D.A. van Heel1, J.O. Lindsay1

1Queen Mary University of London, Centre for Digestive Diseases, London, United Kingdom, 2The Royal London Hospital, Centre for Digestive Diseases, London, United Kingdom

P574.

A recent flare of disease does not prohibit travel: early results of a single centre study in inflammatory bowel disease and travel

Authors:

K. Greveson, T. Shepherd, M. Hamilton, C. Murray, Royal Free Hospital, Gastroenterology, London, United Kingdom